A Study Of PF-06263507 In Patients With Advanced Solid Tumors



Status:Terminated
Conditions:Breast Cancer, Lung Cancer, Ovarian Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:1/11/2019
Start Date:August 8, 2013
End Date:June 29, 2015

Use our guide to learn which trials are right for you!

A PHASE 1, DOSE ESCALATION STUDY OF PF-06263507 IN PATIENTS WITH ADVANCED SOLID TUMORS

To assess the safety and tolerability at increasing dose levels of PF-06263507 in patients
with advanced solid tumors in order to determine the maximum tolerated dose and select the
recommended Phase 2 dose.


Inclusion Criteria:

- Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
or for which no standard therapy is available.

- Performance Status of 0 or 1.

- Adequate bone marrow, kidney, liver, and heart function.

Exclusion Criteria:

- Brain metastases requiring steroids.

- Major surgery or anti-cancer therapy within 4 weeks of study treatment start.

- Active bacterial, fungal or viral infection.
We found this trial at
4
sites
Detroit, Michigan 48201
?
mi
from
Detroit, MI
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19111
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials